Cargando…
Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943345/ https://www.ncbi.nlm.nih.gov/pubmed/29563632 http://dx.doi.org/10.1038/s41416-018-0040-y |
| _version_ | 1783321604786225152 |
|---|---|
| author | Shinozaki, Eiji Yoshino, Takayuki Tsuchihara, Katsuya |
| author_facet | Shinozaki, Eiji Yoshino, Takayuki Tsuchihara, Katsuya |
| author_sort | Shinozaki, Eiji |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5943345 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59433452019-04-15 Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' Shinozaki, Eiji Yoshino, Takayuki Tsuchihara, Katsuya Br J Cancer Correspondence Nature Publishing Group UK 2018-03-22 2018-05-01 /pmc/articles/PMC5943345/ /pubmed/29563632 http://dx.doi.org/10.1038/s41416-018-0040-y Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0). |
| spellingShingle | Correspondence Shinozaki, Eiji Yoshino, Takayuki Tsuchihara, Katsuya Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title | Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title_full | Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title_fullStr | Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title_full_unstemmed | Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title_short | Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' |
| title_sort | reply to `comment on `clinical significance of braf non-v600e mutations on the therapeutic effects of anti-egfr monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the biomarker research for anti-egfr monoclonal antibodies by comprehensive cancer genomics (breac) study'' |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943345/ https://www.ncbi.nlm.nih.gov/pubmed/29563632 http://dx.doi.org/10.1038/s41416-018-0040-y |
| work_keys_str_mv | AT shinozakieiji replytocommentonclinicalsignificanceofbrafnonv600emutationsonthetherapeuticeffectsofantiegfrmonoclonalantibodytreatmentinpatientswithpretreatedmetastaticcolorectalcancerthebiomarkerresearchforantiegfrmonoclonalantibodiesbycomprehensivecancergenomicsbreacs AT yoshinotakayuki replytocommentonclinicalsignificanceofbrafnonv600emutationsonthetherapeuticeffectsofantiegfrmonoclonalantibodytreatmentinpatientswithpretreatedmetastaticcolorectalcancerthebiomarkerresearchforantiegfrmonoclonalantibodiesbycomprehensivecancergenomicsbreacs AT tsuchiharakatsuya replytocommentonclinicalsignificanceofbrafnonv600emutationsonthetherapeuticeffectsofantiegfrmonoclonalantibodytreatmentinpatientswithpretreatedmetastaticcolorectalcancerthebiomarkerresearchforantiegfrmonoclonalantibodiesbycomprehensivecancergenomicsbreacs |